List of Figures and Tables

Figure 1.1: Anticancer drug: Cyclophosphamide (a) 2D structure; (b) 3D view........ 3
Figure 1.2: Metabolism of cyclophosphamide......................................................... 6
Figure 1.3: Mechanism of lipid peroxidation.............................................................. 10
Figure 4.1: Leaves and aerial part of Phyllanthus fraternus............................................ 45
Figure 4.2: Leaves and tree of Aegle marmelos.......................................................... 46
Figure 4.3: GC-MS analysis of Phyllanthus fraternus................................................... 57
Figure 4.4: GC-MS analysis of Aegle marmelos.......................................................... 60
Figure 5.1: Protective effect of aqueous extracts of P. fraternus and A. marmelos in serum transaminases against CPA-induced hepatotoxicity .................. 81
Figure 5.2: Protective effect of aqueous extracts of P. fraternus and A. marmelos in serum phosphatases against CPA-induced hepatotoxicity ............... 82
Figure 5.3: Protective effect of aqueous extracts of P. fraternus and A. marmelos in serum LDH and cholesterol against CPA-induced hepatotoxicity ...... 83
Figure 5.4: Protective effect of aqueous extracts of P. fraternus and A. marmelos in serum total bilirubin and albumin against CPA-induced hepatotoxicity..... 84
Figure 5.5: Protective effect of aqueous extracts of P. fraternus and A. marmelos in LPO against CPA-induced hepatotoxicity .............................................. 85
Figure 5.6: Protective effect of aqueous extracts of P. fraternus and A. marmelos in SOD and CAT against CPA-induced hepatotoxicity ....................... 86
Figure 5.7: Protective effect of aqueous extracts of P. fraternus and A. marmelos on haematology against CPA-induced hepatotoxicity ................................. 87
Figure 5.8: Histopathological study of liver................................................................. 88
Figure 6.1: Protective effect of aqueous extracts of P. fraternus and A. marmelos in KSI, serum BUN and creatinine against CPA-induced nephrotoxicity..... 102
Figure 6.2: Protective effect of aqueous extracts of P. fraternus and A. marmelos in LPO, SOD and CAT against CPA-induced nephrotoxicity ................. 103
Figure 6.3: Histopathological study of kidney............................................................. 104
Figure 7.1: Effect of aqueous extracts of *P. fraternus* and *A. marmelos* in GSI against CPA-induced reproductive toxicity ........................................... 122

Figure 7.2: Effect of aqueous extracts of *P. fraternus* and *A. marmelos* in sperm count, motility and viability against CPA-induced reproductive Toxicity ........................................................................................................ 123

Figure 7.3: Effect of aqueous extracts of *P. fraternus* and *A. marmelos* in LPO, SOD and CAT against CPA-induced reproductive toxicity ......................... 124

Figure 7.4: Histopathological study of testis .......................................................... 125

Table 1.1: Physical and chemical properties of cyclophosphamide ..................... 4

Table 4.1: Chemical analysis for phytoconstituents in the aqueous extracts of *P. fraternus* and *A. marmelos* ........................................................................................................ 56

Table 4.2: Phytoconstituents identified in the extract of *P. fraternus* based on GC-MS analysis ........................................................................................................ 58

Table 4.3: Phytoconstituents identified in the extract of *A. marmelos* based on GC-MS analysis ........................................................................................................ 61

Table 5.1: Percentage protection of various biochemical parameters, antioxidant activities and haematological parameters after treatment with AEPF and AEAM against CPA-induced hepatotoxicity in mice ........................................... 92

Table 6.1: Percentage protection of various biochemical parameters and antioxidant activities after treatment with AEPF and AEAM against CPA-induced nephrotoxicity in mice ................................................................. 108